The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate.

[1]  T. Hien,et al.  Avian influenza A (H5N1) , 2005, Journal of Clinical Virology.

[2]  M. Kiso,et al.  Characterization of H5N1 influenza A viruses isolated during the 2003-2004 influenza outbreaks in Japan. , 2005, Virology.

[3]  D. Suarez,et al.  Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenza. , 2004, Vaccine.

[4]  M. Zambon,et al.  Confronting the avian influenza threat: vaccine development for a potential pandemic , 2004, The Lancet Infectious Diseases.

[5]  Y Li,et al.  The evolution of H5N1 influenza viruses in ducks in southern China. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[6]  Y. Guan,et al.  Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern Asia , 2004, Nature.

[7]  R. Webster,et al.  H5N1 influenza: a protean pandemic threat. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[8]  Y. Guan,et al.  Responsiveness to a pandemic alert: use of reverse genetics for rapid development of influenza vaccines , 2004, The Lancet.

[9]  Y. Guan,et al.  Antigenic differences between H5N1 human influenza viruses isolated in 1997 and 2003. , 2004, The Journal of veterinary medical science.

[10]  J. Peiris,et al.  Re-emergence of fatal human influenza A subtype H5N1 disease , 2004, The Lancet.

[11]  R. Webster,et al.  Are We Ready for Pandemic Influenza? , 2003, Science.

[12]  Yoshihiro Kawaoka,et al.  Exploitation of Nucleic Acid Packaging Signals To Generate a Novel Influenza Virus-Based Vector Stably Expressing Two Foreign Genes , 2003, Journal of Virology.

[13]  Maria Zambon,et al.  Boosting immunity to influenza H5N1 with MF59-adjuvanted H5N3 A/Duck/Singapore/97 vaccine in a primed human population. , 2003, Vaccine.

[14]  Chin-fen Yang,et al.  Multiple amino acid residues confer temperature sensitivity to human influenza virus vaccine strains (FluMist) derived from cold-adapted A/Ann Arbor/6/60. , 2003, Virology.

[15]  N. Cox,et al.  Evaluation of a genetically modified reassortant H5N1 influenza A virus vaccine candidate generated by plasmid-based reverse genetics. , 2003, Virology.

[16]  G. Schild,et al.  Preparation of vaccines against H5N1 influenza. , 2002, Vaccine.

[17]  A. Osterhaus,et al.  Cold-adapted live influenza vaccine versus inactivated vaccine: systemic vaccine reactions, local and systemic antibody response, and vaccine efficacy. A meta-analysis. , 2002, Vaccine.

[18]  M. Zambon,et al.  Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenza , 2001, The Lancet.

[19]  H. Goto,et al.  Generation of a Highly Pathogenic Avian Influenza A Virus from an Avirulent Field Isolate by Passaging in Chickens , 2001, Journal of Virology.

[20]  Yoshihiro Kawaoka,et al.  Pandemic Threat Posed by Avian Influenza A Viruses , 2001, Clinical Microbiology Reviews.

[21]  Lihan K. Yan,et al.  Efficacy of vaccination with live attenuated, cold-adapted, trivalent, intranasal influenza virus vaccine against a variant (A/Sydney) not contained in the vaccine. , 2000, The Journal of pediatrics.

[22]  Tokiko Watanabe,et al.  Generation of influenza A viruses entirely from cloned cDNAs. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Maricarmen García,et al.  Baculovirus-derived hemagglutinin vaccines protect against lethal influenza infections by avian H5 and H7 subtypes. , 1999, Vaccine.

[24]  K. Subbarao,et al.  Recombinant influenza A virus vaccines for the pathogenic human A/Hong Kong/97 (H5N1) viruses. , 1999, The Journal of infectious diseases.

[25]  R. Webster,et al.  Human influenza A H5N1 virus related to a highly pathogenic avian influenza virus , 1998, The Lancet.

[26]  N. Cox,et al.  Characterization of an avian influenza A (H5N1) virus isolated from a child with a fatal respiratory illness. , 1998, Science.

[27]  R. Webster,et al.  Survey of the hemagglutinin (HA) cleavage site sequence of H5 and H7 avian influenza viruses: amino acid sequence at the HA cleavage site as a marker of pathogenicity potential. , 1996, Avian diseases.

[28]  R. Webster,et al.  Origin and molecular changes associated with emergence of a highly pathogenic H5N2 influenza virus in Mexico. , 1995, Virology.

[29]  C. Naeve,et al.  Is virulence of H5N2 influenza viruses in chickens associated with loss of carbohydrate from the hemagglutinin? , 1984, Virology.

[30]  R. Chanock,et al.  Association of serum anti-neuraminidase antibody with resistance to influenza in man. , 1972, The New England journal of medicine.

[31]  J. Pearson.  International Standards for the Control of Avian Influenza , 2003, Avian diseases.

[32]  D. Alexander.  Newcastle Disease Diagnosis , 1988 .

[33]  E. D. Kilbourne.  Future influenza vaccines and the use of genetic recombinants. , 1969, Bulletin of the World Health Organization.